Human Genome Epidemiology Literature Finder
Records 1 - 4 (of 4 Records) |
Query Trace: Xeroderma Pigmentosum and CDA[original query] |
---|
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 14 (6): 1797-803. Tibaldi Carmelo, Giovannetti Elisa, Vasile Enrico, Mey Valentina, Laan Adrie C, Nannizzi Sara, Di Marsico Roberta, Antonuzzo Andrea, Orlandini Cinzia, Ricciardi Simona, Del Tacca Mario, Peters Godefridus J, Falcone Alfredo, Danesi Roma |
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2012 May 118 (9): 2466-75. Joerger Markus, Burgers Sjaak A, Baas Paul, Smit Egbert F, Haitjema Tjeerd J, Bard Martin P L, Doodeman Valerie D, Smits Paul H M, Vincent Andrew, Huitema Alwin D R, Beijnen Jos H, Schellens Jan H |
Genetic polymorphisms of XPD and CDA and lung cancer risk. Oncology letters 2012 Aug 4 (2): 247-251. Zhou Min, Wan Huan-Ying, Gao Bei-Li, Ding Yong-Jie, Jun Rong-X |
Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. Genetics and molecular research : GMR 2014 13 (2): 3310-8. Zhou M, Ding Y J, Feng Y, Zhang Q R, Xiang Y, Wan H |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source: